No Data
No Data
No Data
No Data
No Data
Q BioMed Inc. Provides Update to Shareholders
NEW YORK, June 23, 2023 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector, provides
PR NewswireJun 23, 2023 08:00 ET
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Patent From United States Patent Office and Notice of Allowance for Europe
Company's Liver Cancer Drug Candidate IP Portfolio strengthened Company provides operational update on strategic opportunities NEW YORK, April 14, 2023 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a
PR NewswireApr 14, 2023 08:06 ET
Q BioMed Inc. (OTCMKTS:QBIO) Short Interest Up 24.6% in February
Q BioMed Inc. (OTCMKTS:QBIO – Get Rating) was the recipient of a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 37,500 shares,
kopsourceMar 4, 2023 11:42 ET
Q BioMed Chemotherapy Uttroside B for Liver Cancer to Get US Patent
Seeking AlphaFeb 10, 2023 08:39 ET
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent From United States Patent Office
Uttroside B Has Shown Promising Results in Initial Pre-Clinical Testing NEW YORK, Feb. 10, 2023 /PRNewswire/ -- Q BioMed Inc. (OTCQB:QBIO) a biotech acceleration and commercial stage company focused on licensing and
PR NewswireFeb 10, 2023 08:05 ET
Short Interest in Q BioMed Inc. (OTCMKTS:QBIO) Expands By 21.2%
Q BioMed Inc. (OTCMKTS:QBIO – Get Rating) was the recipient of a significant growth in short interest in the month of December. As of December 30th, there was short interest totalling 189,900 shares,
Defense WorldJan 22, 2023 03:51 ET
No Data
No Data